Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04373512 · ClinicalTrials.gov registry record · Phase 2
Intravesical Lactobacillus to Reduce Urinary Symptoms After Spinal Cord Injury
A Phase 2 study, sponsored by Medstar Health Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 182
- Enrollment target
NCT04373512 is a Phase 2 study that has completed, run by Medstar Health Research Institute. The registered enrollment target is 182 participants.
The verdict
NCT04373512, a Phase 2 study, has completed, sponsored by Medstar Health Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 182 participants
- Enrollment target
Study Summary
The objectives of the proposed research among this population are: 1) to define clinically meaningful change (i.e. differentiating states of health and illness) with respect to urinary symptoms, urine inflammation, cultivable bacteria, and the urine ecosystem; and 2) to determine the optimal intravesical Lactobacillus RhamnosusGG (LGG®) dose to be used to reduce urinary symptoms in a future clinical trial.
Interventions
- DRUG Culturelle 10 Billion CFU Capsule (2 doses)
- DRUG Culturelle 10 Billion CFU Capsule (4 doses)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 182 participants |
| Start Date | 2020-05-20 |
| Est. Completion | 2025-02-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04373512
The ClinicalTrials.gov registry entry for NCT04373512 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 182 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medstar Health Research Institute, which has 115 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Culturelle 10 Billion CFU Capsule (2 doses) is the first listed.
NCT04373512 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04373512 about?
NCT04373512 is a clinical study titled "Intravesical Lactobacillus to Reduce Urinary Symptoms After Spinal Cord Injury". The objectives of the proposed research among this population are: 1) to define clinically meaningful change (i.e. differentiating states of health and illness) with respect to urinary symptoms, urine inflammation, cultivable bacteria, and the urine ecosystem; and 2) to determine the optimal intrave...
What is the current status of trial NCT04373512?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 182 participants. The study started on 2020-05-20. Estimated completion is 2025-02-14.
What interventions are being tested in trial NCT04373512?
The interventions under investigation include: Culturelle 10 Billion CFU Capsule (2 doses) (DRUG), Culturelle 10 Billion CFU Capsule (4 doses) (DRUG).
Who is sponsoring clinical trial NCT04373512?
This trial is sponsored by Medstar Health Research Institute, which has 115 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.